<DOC>
	<DOCNO>NCT00297596</DOCNO>
	<brief_summary>This phase II study combination oxaliplatin trastuzumab first second line therapy patient stage IV , metastatic breast cancer</brief_summary>
	<brief_title>Trastuzumab Oxaliplatin Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Eligible patient receive minimum six cycle combination therapy . If patient still respond oxaliplatin 6 cycle , oxaliplatin may continue trastuzumab 10 cycle investigator 's discretion . After discontinue oxaliplatin/trastuzumab combination , patient continue single agent trastuzumab disease progression . Trastuzumab administer 8 mg/kg load dose intravenous ( IV ) infusion 90 minute day 1 cycle 1 . Subsequent dos administer 6 mg/kg IV dose 30 minute . Oxaliplatin administer dose 130 mg/ m2 120 minute day 1 cycle , follow standard antiemetic premedications . 21 day cycle . For first cycle , trastuzumab administer oxaliplatin ; however subsequent cycle , oxaliplatin infuse prior trastuzumab</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Females ≥ 18 year age Histologically confirm breast cancer HER2/neu positive ( 3+ IHC FISH + ) evidence metastatic disease . Tumor may estrogen progesterone receptor type Measurable disease RECIST ECOG ≤ 2 Patients know evidence brain metastasis eligible asymptomatic complete therapy ( surgery , radiotherapy , and/or steroid ) Baseline LVEF value within institutional normal range Any number prior hormonal therapy treatment adjuvant set metastatic disease . A subject must progress hormonal therapy hormonal therapy ( include birth control pill ) must discontinue study entry . Prior chemotherapy adjuvant set one prior chemotherapy regimen metastatic disease allow . Patients may receive one prior trastuzumab/chemotherapy contain regimen prior single agent trastuzumab . Prior radiation therapy adjuvant set metastatic disease , provide site evaluable disease . All prior chemotherapy , trastuzumab radiation therapy complete &gt; 2 week enrollment . Patients receive bisphosphonate therapy eligible . However , bisphosphonate start within &lt; 2 month prior enrollment , bone lesion evaluate response patient must another site metastatic disease either measurable evaluable response . Patients must recover toxicity due prior therapy . Lab value accordance protocol Patients must nonpregnant nonlactating . Patients childbearing potential must implement effective method contraception study ( birth control pill allow ) . Bone disease ineligible Patients receive 1 prior chemotherapy regimen metastatic disease ineligible . Patients history cancer except curativelytreated carcinoma cervix situ nonmelanomatous skin cancer . Active serious infection underlie medical condition would impair ability receive protocol treatment . Uncontrolled nervous system metastases Dementia significantly alter mental status would interfere proper consenting . Receiving investigational therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>HER2/neu+</keyword>
</DOC>